---
title: "Elicio Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295842534.md"
datetime: "2026-08-13T20:30:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295842534.md)
  - [en](https://longbridge.com/en/news/295842534.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295842534.md)
---

# Elicio Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.43, beating the estimate of USD -0.5375.

EBIT: As of FY2026 Q2, the actual value is USD -8.217 M.

### Financial Performance for Three Months Ended June 30, 2026

#### Research and Development (R&D) Expense

Elicio Therapeutics, Inc.’s R&D expense for the second quarter of 2026 was $6.8 million, a decrease of $0.2 million compared to $7.0 million for the second quarter of 2025. This decrease was primarily due to lower clinical trial costs as the Phase 2 study of ELI-002 7P transitioned from active dosing to the follow-up phase.

#### General and Administrative (G&A) Expense

G&A expense for the second quarter of 2026 was $3.6 million, an increase of $0.5 million from $3.1 million in the second quarter of 2025. This rise was mainly attributed to increased company headcount, leading to higher personnel costs, and a slight increase in professional fees.

#### Total Operating Expenses

Total operating expenses were $10.429 million for the second quarter of 2026, compared to $10.091 million for the same period in 2025.

#### Loss from Operations

Loss from operations for the second quarter of 2026 was - $10.429 million, compared to - $10.091 million for the second quarter of 2025.

#### Total Other Income (Expense), Net

Total other income, net, was $2.212 million for the second quarter of 2026, compared to - $0.470 million for the second quarter of 2025.

#### Net Loss

Net loss for the second quarter of 2026 was - $8.217 million, an improvement from - $10.561 million for the second quarter of 2025.

#### Comprehensive Loss

Comprehensive loss was - $8.221 million for the second quarter of 2026, compared to - $10.487 million for the second quarter of 2025.

#### Cash and Cash Equivalents

As of June 30, 2026, cash and cash equivalents totaled $23.480 million, compared to $18.563 million as of December 31, 2025.

#### Financing Activities

Elicio Therapeutics, Inc. raised net proceeds of $16.6 million in the second quarter of 2026, contributing to aggregate net proceeds of approximately $24.4 million year-to-date through its at-the-market program. In July 2026, the company raised aggregate gross proceeds of approximately $15.0 million in a registered direct offering.

#### Balance Sheet Highlights

As of June 30, 2026, total assets were $31.330 million, compared to $25.862 million as of December 31, 2025. Total liabilities were $23.393 million on June 30, 2026, down from $24.226 million on December 31, 2025. Total stockholders’ equity increased to $7.937 million as of June 30, 2026, from $1.636 million as of December 31, 2025.

### Outlook / Guidance

Elicio Therapeutics, Inc. anticipates that its current cash and cash equivalents will support operations into the first quarter of 2027. The company plans to initiate a Phase 1 combination study of ELI-002 7P in metastatic pancreatic cancer in the fourth quarter of 2026. This study will evaluate ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor.

### Related Stocks

- [ELTX.US](https://longbridge.com/en/quote/ELTX.US.md)

## Related News & Research

- [Elicio opens Phase 1 neoadjuvant ELI-002 7P trial in resectable pancreatic cancer at MSK](https://longbridge.com/en/news/295403408.md)
- [Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering | ELTX Stock News](https://longbridge.com/en/news/291495074.md)
- [Elicio Therapeutics posts AMPLIFY-7P presentation on ELI-002 7P in metastatic mKRAS pancreatic cancer](https://longbridge.com/en/news/290828766.md)
- [Elicio Therapeutics Pancreatic Cancer Study Disappoints](https://longbridge.com/en/news/289811449.md)
- [Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug](https://longbridge.com/en/news/290083011.md)